FDA Awards Priority Review Voucher for Rare Pediatric Disease Drug
January 09, 2025
January 09, 2025
WASHINGTON, Jan. 9 (TNSFR) -- The Food and Drug Administration (FDA) has granted a priority review voucher to Neurocrine Biosciences, Inc. for its drug CRENESSITY (crinecerfont), which was approved on December 13, 2024.
This drug is indicated for glucocorticoid replacement to manage androgen levels in adults and children aged four and older with classic congenital adrenal hyperplasia.
The voucher, issued under the Rare Pediatric Disease Priority Review Voucher Program . . .
This drug is indicated for glucocorticoid replacement to manage androgen levels in adults and children aged four and older with classic congenital adrenal hyperplasia.
The voucher, issued under the Rare Pediatric Disease Priority Review Voucher Program . . .